The platform combines two innovations: (1) gold nanoarrayswith epithelial cell adhesion molecule (EpCAM)-specific aptamers toselectively isolate tumor-derived EVs from plasma and (2) CRISPR/Cas13a-encapsulatedliposomes that fuse with EVs to form nanoscale reactors. This evidence concerns the gene EPCAM and neoplasm.